BIOMAT Database Logo BIOMAT Database Logo

Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal. 1994

J S Fowler, and N D Volkow, and J Logan, and G J Wang, and R R MacGregor, and D Schyler, and A P Wolf, and N Pappas, and D Alexoff, and C Shea
Chemistry Department, Brookhaven National Laboratory, Upton, New York 11973.

L-Deprenyl (Selegeline) is an enzyme-activated irreversible inhibitor of monoamine oxidase B (MAO B; EC 1.4.3.4). It is used to treat Parkinson's disease at a dose of 5 mg twice a day. Since enzyme inhibition is irreversible, the recovery of functional enzyme activity after withdrawal from L-deprenyl requires the synthesis of new enzyme. We have measured a 40 day half-time for brain MAO B synthesis in Parkinson's disease and in normal subjects after withdrawal from L-deprenyl. This is the first measurement of the synthesis rate of a specific protein in the living human brain. L-Deprenyl is currently used by 50,000 patients with Parkinson's disease in the United States and its use is expected to increase with reports that it may be beneficial in Alzheimer's disease. The slow turnover of brain MAO B suggests that the current clinical dose of L-deprenyl may be excessive and that the clinical efficacy of reduced dosing should be evaluated. Such an evaluation may have mechanistic importance as well as an impact on reducing the side effects and the costs arising from excessive drug use.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D008995 Monoamine Oxidase An enzyme that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in mitochondrial membranes, whether in nerve terminals, the liver, or other organs. Monoamine oxidase is important in regulating the metabolic degradation of catecholamines and serotonin in neural or target tissues. Hepatic monoamine oxidase has a crucial defensive role in inactivating circulating monoamines or those, such as tyramine, that originate in the gut and are absorbed into the portal circulation. (From Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 8th ed, p415) EC 1.4.3.4. Amine Oxidase (Flavin-Containing),MAO,MAO-A,MAO-B,Monoamine Oxidase A,Monoamine Oxidase B,Type A Monoamine Oxidase,Type B Monoamine Oxidase,Tyramine Oxidase,MAO A,MAO B,Oxidase, Monoamine,Oxidase, Tyramine
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

J S Fowler, and N D Volkow, and J Logan, and G J Wang, and R R MacGregor, and D Schyler, and A P Wolf, and N Pappas, and D Alexoff, and C Shea
Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl.
January 1987, Advances in neurology,
J S Fowler, and N D Volkow, and J Logan, and G J Wang, and R R MacGregor, and D Schyler, and A P Wolf, and N Pappas, and D Alexoff, and C Shea
Test-retest reproducibility of [11C]-L-deprenyl-D2 binding to MAO-B in the human brain.
December 2017, EJNMMI research,
J S Fowler, and N D Volkow, and J Logan, and G J Wang, and R R MacGregor, and D Schyler, and A P Wolf, and N Pappas, and D Alexoff, and C Shea
Recovery of MAO-B enzyme activity after (-)deprenyl (selegiline) pretreatment, measured in vivo.
January 1989, Acta physiologica Hungarica,
J S Fowler, and N D Volkow, and J Logan, and G J Wang, and R R MacGregor, and D Schyler, and A P Wolf, and N Pappas, and D Alexoff, and C Shea
Responses of forebrain neurons to the MAO-B blocker L-deprenyl.
January 1995, Brain research bulletin,
J S Fowler, and N D Volkow, and J Logan, and G J Wang, and R R MacGregor, and D Schyler, and A P Wolf, and N Pappas, and D Alexoff, and C Shea
Turnover of monoamine oxidase B (MAO-B) in pig brain by positron emission tomography using 11C-L-deprenyl.
January 1990, Journal of neural transmission. Supplementum,
J S Fowler, and N D Volkow, and J Logan, and G J Wang, and R R MacGregor, and D Schyler, and A P Wolf, and N Pappas, and D Alexoff, and C Shea
Improvement of cognitive function by MAO-B inhibitor L-deprenyl in aged rats.
June 1991, Pharmacology, biochemistry, and behavior,
J S Fowler, and N D Volkow, and J Logan, and G J Wang, and R R MacGregor, and D Schyler, and A P Wolf, and N Pappas, and D Alexoff, and C Shea
Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography.
January 2011, Neurochemistry international,
J S Fowler, and N D Volkow, and J Logan, and G J Wang, and R R MacGregor, and D Schyler, and A P Wolf, and N Pappas, and D Alexoff, and C Shea
Anti-depressant potentiation of 5-hydroxytryptophan by L-deprenyl, an MAO "type B" inhibitor.
January 1978, Journal of neural transmission,
J S Fowler, and N D Volkow, and J Logan, and G J Wang, and R R MacGregor, and D Schyler, and A P Wolf, and N Pappas, and D Alexoff, and C Shea
Effects of long-term treatment with a monoamine oxidase B inhibitor, selegeline (L-deprenyl), on amino acid transmitter systems in the ageing rat brain.
January 1995, Proceedings of the Western Pharmacology Society,
J S Fowler, and N D Volkow, and J Logan, and G J Wang, and R R MacGregor, and D Schyler, and A P Wolf, and N Pappas, and D Alexoff, and C Shea
Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301.
May 2009, Clinical pharmacology and therapeutics,
Copied contents to your clipboard!